Drug Profile
Rotavirus vaccine - PATH
Alternative Names: Trivalent P2-VP8; Trivalent rotavirus P2-VP8 subunit vaccine - SK Bioscience; Trivalent rotavirus vaccine - SK Bioscience; TV P2-VP8Latest Information Update: 05 Dec 2022
Price :
$50
*
At a glance
- Originator PATH
- Class Rotavirus vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rotavirus infections
Most Recent Events
- 09 Sep 2022 PATH and SK Bioscience completes a phase II trial for Rotavirus infections (In neonates, In infants, Prevention) in South Africa (IM) (NCT04344054)
- 08 Apr 2021 PATH and SK Bioscience re-initiates a phase III trial for Rotavirus infections (Prevention, In infants) in Zambia (IM) that was temporarily suspended due to COVID-2019(NCT04010448)
- 22 Feb 2021 Phase-II clinical trials in Rotavirus infections (In infants, In neonates, Prevention) in South Africa (IM) (NCT04344054)